The honest bottom line is that this molecule has a strong rodent story and a failed human one. A short synthetic peptide matching the C-terminal end of human growth hormone, developed in Australia and taken into the clinic as AOD9604, reduced fat mass in obese rodents without raising IGF-1, then went through Phase 1 and Phase 2 in roughly nine hundred people and did not beat placebo in the confirmatory trial. What survived the program is a safety record rather than an efficacy finding, and that distinction is where most of the confusion about this compound begins.
The rodent evidence for the growth hormone 176-191 fragment is consistent while the human evidence is not, with a six-month Phase 2b trial in several hundred obese adults failing to separate from placebo on body weight before the obesity program was discontinued in 2007.
The whole point of the fragment was subtraction, not addition. Full-length growth hormone does reduce fat mass in adults, but it drags along raised IGF-1, tissue growth, fluid retention, joint pain, and worsening glucose control, which ruled it out as an obesity treatment. The research question at Monash University was whether the fat-metabolizing part of the molecule could be separated from everything else, and that structural question was settled long before any question about whether the result held in people.
AOD9604 is a synthetic hexadecapeptide corresponding to hGH 177 to 191 with an added N-terminal tyrosine, developed on the explicit and testable hypothesis that growth hormone's effect on adipose tissue could be reproduced without its growth-promoting activity.
Most of what looks impressive about this compound traces back to two standard rodent obesity models and a set of endpoints chosen to test one specific hypothesis. The animal data are internally consistent: less fat gained, higher lipolytic markers, flat IGF-1. The catch sits in what those models were asking, since slowing fat accumulation in a rapidly fattening animal is a far easier effect to produce than stripping established fat from a weight-stable one.
In obese rodent models, chronic dosing reduced adipose depot mass by roughly a quarter to a half relative to controls without raising circulating IGF-1, and the response disappeared entirely in beta-3 adrenergic receptor knockout mice.
The human program was designed properly and reported poorly. Randomised, double-blind, placebo-controlled trials of an oral formulation ran from the early 2000s to roughly 2007, and the encouraging twelve-week result that still drives this compound's reputation was followed by a longer confirmatory trial that failed. Anyone weighing the human evidence is weighing two results that were never published to the same standard.
The program's decisive study, a six-month Phase 2b in several hundred obese adults, did not separate from placebo on the primary body-weight endpoint, and neither that result nor the earlier positive twelve-week result was published as a complete peer-reviewed report.
Rodent-to-human failure in obesity pharmacology is rarely mysterious, and this case has a prime suspect with a long record of sinking drug programs. The literature does not definitively settle between the competing explanations, but the receptor mismatch, the softer animal endpoint, and the uncertain oral exposure all cut the same way: the human question may never have been fairly asked, and it certainly was not answered in the affirmative.
| Factor | Rodent studies | Human trials |
|---|---|---|
| Beta-3 adrenergic receptor | Prominent in white and brown adipose tissue | Little functional receptor in adult white fat |
| Endpoint tested | Attenuated weight gain in fattening animals | Loss of established fat in weight-stable adults |
| Route and exposure | Injected or high-dose protocols | Oral, facing gut proteases and poor absorption |
| Comparator conditions | Untreated controls | Placebo arm carrying lifestyle and dietary counselling |
The rodent response was tied to beta-3 adrenergic receptor signalling, a pathway rodents depend on heavily for adipose lipolysis but adult humans express only sparsely in white fat, and an entire generation of beta-3 agonists had already failed in human obesity trials for that same reason.
Mechanism is where this compound's account is strongest in description and weakest in proof. Published work associates the peptide with more lipolysis and less lipogenesis in adipose tissue while leaving the growth hormone receptor cascade untouched, which is precisely the separation the original hypothesis called for. Missing is the piece that would make it pharmacology rather than observation: no receptor for the peptide itself has been characterised.
Because no defined binding site for the fragment has been established, its published mechanism is best described as an observed downstream signalling association in rodent adipose tissue rather than a mapped ligand and receptor interaction, and an ex vivo lipolysis signal does not predict net fat loss in a whole organism.
This is the part of the record that holds up. Across the tested doses the fragment did not move IGF-1 or glucose handling the way full-length growth hormone reliably does, which matters because IGF-1 is the mediator behind acromegalic features, joint symptoms, carpal tunnel syndrome, and the proliferative concerns that make growth hormone unsuitable for casual use. The trap is reading a clean hormonal panel as evidence that something useful happened.
| Parameter | Full-length growth hormone | hGH C-terminal fragment |
|---|---|---|
| Circulating IGF-1 | Raised, driving tissue growth and unwanted effects | No clinically meaningful change at tested doses |
| Fasting glucose | Raised; can unmask impaired glucose tolerance | No reported deterioration |
| Insulin sensitivity | Reduced; frankly diabetogenic | No equivalent decline reported |
Human trials and the 2013 pooled safety review found no clinically meaningful change in IGF-1, fasting glucose, or insulin sensitivity, which establishes that the fragment is not acting as a growth hormone mimetic and says nothing about whether it does anything useful.
Safety is the strongest part of this literature and also the part most often stretched past what it covers. The 2013 pooled review of the Phase 1 and Phase 2 program found little to report, which is a real finding about a pharmaceutical-grade oral product given for a few months. It says nothing about an injected vial of unverified content used indefinitely.
The 2013 pooled review covering roughly nine hundred Phase 1 and Phase 2 participants reported no dose-limiting toxicity and no serious adverse events attributed to the compound, but it examined a defined oral pharmaceutical formulation, so its safety record does not transfer to an injected product of unverified content.
When the obesity program was shelved, the compound was repositioned toward joints, and the evidence followed it only as far as small animal models. The reported cartilage results point in a favourable direction, though the strongest arms combined the peptide with hyaluronic acid, which carries established effects of its own in the same models. The decisive fact is an absence rather than a finding.
The joint and cartilage evidence consists of small rabbit and rat osteoarthritis studies from a handful of groups, with no published randomised controlled human trial of this peptide for osteoarthritis, cartilage repair, joint pain, tendon healing, or injury recovery.
The gaps here go beyond the ordinary limitations every literature carries, because several of them bear on whether the evidence describes the product actually in circulation. Publication completeness, sponsor independence, and route mismatch compound one another, so the most widely repeated numbers are also the least scrutinised.
Settling the question would take an adequately powered, independently conducted, preregistered randomised trial of the marketed route and dose, with body composition measured by DXA rather than scale weight alone and at least twelve months of follow-up published in full regardless of outcome, and no such trial exists.
Lining the marketing up against the record makes the mismatch easy to see. Three claims hold, and all three concern rodents or safety rather than fat loss in people, while the rest have never been tested in a controlled human study. The most common rhetorical move in commercial copy is to present a classification document, whether a food-ingredient determination or a doping ban, as though it were evidence of effect.
| Claim in circulation | What the record contains | Evidence level |
|---|---|---|
| Reduced fat mass | Consistent results in obese rodent models | Animal only |
| No IGF-1 elevation | Human trials plus the 2013 pooled review | Human |
| Well tolerated at tested doses | Oral Phase 1 and Phase 2 safety data | Human safety, not efficacy |
| Spot fat reduction, muscle preservation, joint repair, injury recovery, anti-ageing | Nothing | Untested in humans |
| Food-ingredient status or doping ban cited as proof of effect | Classification and safety documents only | Not an efficacy finding |
The three claims with published support concern fat loss in obese rodents, an unchanged IGF-1 level, and short-term tolerability at tested oral doses, while targeted fat reduction, muscle preservation, cartilage repair, and injury recovery in humans have never been tested in a controlled trial, and the World Anti-Doping Agency's listing of AOD-9604 and hGH 176-191 is an administrative classification rather than a statement of potency.
Educational use only. This article describes what the published scientific and clinical literature reports about HGH Fragment 176-191. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
